Clinical Drug Investigation

, Volume 28, Issue 8, pp 465–477 | Cite as

Practical Issues with Amisulpride in the Management of Patients with Schizophrenia

  • Luca Pani
  • José M. Villagrán
  • Vassilis P. Kontaxakis
  • Köksal Alptekin
Review Article


Amisulpride is an atypical antipsychotic with a significantly greater effect size than first-generation, typical antipsychotics, and efficacy at least similar to that of olanzapine and risperidone in large-scale clinical trials in schizophrenia. Amisulpride provides greater improvement in positive and negative symptoms of schizophrenia, a better long-term outcome than typical antipsychotics, and distinct tolerability advantages over typical antipsychotics, which are reported to cause extrapyramidal symptoms (EPS) in 20–50% of patients. In addition, amisulpride is associated with significantly less weight gain than olanzapine and risperidone, does not increase body mass index, and favourably influences lipid profiles. In many patients with schizophrenia, adverse events impair adherence to treatment, and switching from typical or atypical antipsychotic therapy to amisulpride may be clinically appropriate. Observational drug-utilization studies suggest that many physicians switch to amisulpride because of fewer EPS and/or less weight gain and improved patient adherence. Cross-tapering (over 4 weeks), rather than abrupt cessation of pre-switch treatment, is preferred. Amisulpride has a low risk of drug-drug interactions, and, during cross-tapering, patients can remain on concurrent treatments (e.g. anticholinergics and antiparkinsonian agents) until the effective dosage has been reached. An appropriate amisulpride starting dose is 800 mg/day for patients with acute psychotic exacerbations, 400–800 mg/day for patients with predominantly positive symptoms, and 100–300 mg/day for predominantly negative symptoms. Amisulpride may be particularly suitable for clozapine-augmentation therapy in patients with refractory schizophrenia. Indeed, amisulpride is more effective than quetiapine as augmentation therapy in patients partially responsive to clozapine, and several prospective open-label studies and case series have reported promising results for amisulpride/clozapine combination therapy. In three prospective studies, addition of amisulpride 200–800 mg/day to clozapine significantly reduced mean scores on the Brief Psychiatric Rating Scale (BPRS) total (−33% to −35%), Clinical Global Impression (CGI)-Severity scale (−31%), Positive and Negative Syndrome Scale total (−22%), and Scale for the Assessment of Negative Symptoms (−34%). The proportion of responders (CGI score ≥3 or BPRS improvement >20%) was 71–86%. Retrospective case-series analyses have also reported improved psychopathological state, reduced adverse events, and lower clozapine dosage requirement with use of this combination. The pharmacological and clinical profiles of amisulpride suggest that this agent is a viable clinical option when a change of antipsychotic therapy is required in patients with schizophrenia because of lack of efficacy, adverse events and poor adherence to treatment, or for augmentation of clozapine in treatment-resistant illness.


Schizophrenia Clozapine Risperidone Olanzapine Ziprasidone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Dr Alptekin serves as a consultant, advisor and/or lecturer for sanofi-aventis, Lundbeck, Janssen, Pfizer, AstraZeneca, Bristol-Myers Squibb, Sanovel and Eczacibaşi. Over the last 2 years Prof. Pani has served as a consultant, advisor and/or lecturer for AstraZeneca, Bristol-Myers Squibb, Janssen, Johnson & Johnson, Lundbeck, Organon-Schering Plough, Pfizer and sanofi-aventis. The other authors have no conflicts of interest that are directly relevant to the content of this review.

Editorial support for the preparation of this manuscript was provided by Wolters Kluwer Health Medical Communications. This assistance was funded by sanofi-aventis.


  1. 1.
    Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003 Jun; 60(6): 553–64PubMedCrossRefGoogle Scholar
  2. 2.
    Leucht S, Pitschel-Walz G, Engel RR, et al. Amisulpride, an unusual ‘atypical’ antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002 Feb; 159(2): 180–90PubMedCrossRefGoogle Scholar
  3. 3.
    Ziegenbein M, Calliess IT. Clozapine and ziprasidone: a useful combination in patients with treatment-resistant schizophrenia. J Neuropsychiatry Clin Neurosci 2006 Spring; 18(2): 246–7PubMedCrossRefGoogle Scholar
  4. 4.
    Lerner V, Bergman J, Borokhov A, et al. Augmentation with amisulpride for schizophrenic patients nonresponsive to anti-psychotic monotherapy. Clin Neuropharmacol 2005 Mar–Apr; 28(2): 66–71PubMedCrossRefGoogle Scholar
  5. 5.
    Meltzer HY. Treatment of suicidality in schizophrenia. Ann N Y Acad Sci 2001 Apr; 932: 44–58; discussion 58-60PubMedCrossRefGoogle Scholar
  6. 6.
    Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25(2): 233–55PubMedCrossRefGoogle Scholar
  7. 7.
    Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62Suppl. 7: 22–31PubMedGoogle Scholar
  8. 8.
    Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19Suppl. 1: 1–93PubMedGoogle Scholar
  9. 9.
    Rettenbacher MA, Ebenbichler C, Hofer A, et al. Early changes of plasma lipids during treatment with atypical antipsychotics. Int Clin Psychopharmacol 2006 Nov; 21(6): 369–72PubMedCrossRefGoogle Scholar
  10. 10.
    Koro CE, Fedder DO, L’Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002 Nov; 59(11): 1021–6PubMedCrossRefGoogle Scholar
  11. 11.
    Scheen AJ, De Hert MA. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab 2007 Jun; 33(3): 169–75PubMedCrossRefGoogle Scholar
  12. 12.
    Peuskens J, De Hert M, Mortimer A. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. Int Clin Psychopharmacol 2007 May; 22(3): 145–52PubMedCrossRefGoogle Scholar
  13. 13.
    Burns T, Chabannes JP, Demyttenaere K. Switching anti-psychotic medications: general recommendations and switching to amisulpride. Curr Med Res Opin 2002; 18(4): 201–8PubMedCrossRefGoogle Scholar
  14. 14.
    Mortimer A, Martin S, Loo H, et al. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol 2004 Mar; 19(2): 63–9PubMedCrossRefGoogle Scholar
  15. 15.
    Sechter D, Peuskens J, Fleurot O, et al. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology 2002 Dec; 27(6): 1071–81PubMedCrossRefGoogle Scholar
  16. 16.
    Chivers JK, Gommeren W, Leysen JE, et al. Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors. J Pharm Pharmacol 1988 Jun; 40(6): 415–21PubMedCrossRefGoogle Scholar
  17. 17.
    Perrault G, Depoortere R, Morel E, et al. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 1997 Jan; 280(1): 73–82PubMedGoogle Scholar
  18. 18.
    Puech A, Fleurot O, Rein W. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr Scand 1998 Jul; 98(1): 65–72PubMedCrossRefGoogle Scholar
  19. 19.
    Martinot JL, Paillere-Martinot ML, Poirier MF, et al. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology (Berl) 1996 Mar; 124(1–2): 154–8CrossRefGoogle Scholar
  20. 20.
    Peuskens J, Bech P, Moller HJ, et al. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride Study Group. Psychiatry Res 1999 Nov 8; 88(2): 107–17PubMedCrossRefGoogle Scholar
  21. 21.
    Moller HJ, Boyer P, Fleurot O, et al. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. Psychopharmacology (Berl) 1997 Aug; 132(4): 396–401CrossRefGoogle Scholar
  22. 22.
    Mielke DH, Gallant DM, Kessler C. An evaluation of a unique new antipsychotic agent, sulpiride: effects on serum prolactin and growth hormone levels. Am J Psychiatry 1977 Dec; 134(12): 1371–5PubMedGoogle Scholar
  23. 23.
    Alfredsson G, Wiesel FA. Relationships between clinical effects and monoamine metabolites and amino acids in sulpiridetreated schizophrenic patients. Psychopharmacology (Berl) 1990; 101(3): 324–31CrossRefGoogle Scholar
  24. 24.
    Curran MP, Perry CM. Amisulpride: a review of its use in the management of schizophrenia. Drugs 2001; 61(14): 2123–50PubMedCrossRefGoogle Scholar
  25. 25.
    Boyer P, Lecrubier Y, Puech AJ, et al. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 1995 Jan; 166(1): 68–72PubMedCrossRefGoogle Scholar
  26. 26.
    Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry 1999 Apr; 156(4): 610–6PubMedGoogle Scholar
  27. 27.
    Loo H, Poirier-Littre MF, Theron M, et al. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997 Jan; 170: 18–22PubMedCrossRefGoogle Scholar
  28. 28.
    Paillere-Martinot ML, Lecrubier Y, Martinot JL, et al. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 1995 Jan; 152(1): 130–4PubMedGoogle Scholar
  29. 29.
    Soni SD, Mallik A, Schiff AA. Sulpiride in negative schizophrenia: a placebo-controlled double-blind assessment. Hum Psychopharmacol 1990; 5: 233–8CrossRefGoogle Scholar
  30. 30.
    Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64(20): 2291–314PubMedCrossRefGoogle Scholar
  31. 31.
    McKeage K, Plosker GL. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs 2004; 18(13): 933–56PubMedCrossRefGoogle Scholar
  32. 32.
    Coulouvrat C, Dondey-Nouvel L. Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 1999 Jul; 14(4): 209–18PubMedCrossRefGoogle Scholar
  33. 33.
    Baptista T, Alastre T, Contreras Q, et al. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy men: relationship with body weight regulation. Pharmaco-psychiatry 1997 Nov; 30(6): 250–5Google Scholar
  34. 34.
    Baptista T, Molina MG, Martinez JL, et al. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy premenopausal women: relationship with body weight regulation. Pharmacopsychiatry 1997 Nov; 30(6): 256–62PubMedCrossRefGoogle Scholar
  35. 35.
    Buvat-Herbaut BJ. Neuroendocrine effects of sulpiride [in French]. Lille Med 1979 Nov 17; Suppl. 1: 37PubMedGoogle Scholar
  36. 36.
    Ros LT. Changes in the endocrine system in the course of sulpiride therapy [in Polish]. Pol Merkur Lekarski 2001 Dec; 11(66): 532–4PubMedGoogle Scholar
  37. 37.
    Peuskens J. Switching to amisulpride. Curr Med Res Opin 2002; 18Suppl. 3: s23–8PubMedCrossRefGoogle Scholar
  38. 38.
    Weiden PJ. Switching in the era of atypical antipsychotics: an updated review. Postgrad Med 2006 Sep; Special Report: 27-44Google Scholar
  39. 39.
    Buckley PF. Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. J Clin Psychiatry 2007; 68Suppl. 6: 5–9PubMedGoogle Scholar
  40. 40.
    Davis JM. The choice of drugs for schizophrenia. N Engl J Med 2006 Feb 2; 354(5): 518–20PubMedCrossRefGoogle Scholar
  41. 41.
    De Nayer A, De Hert M, Scheen A, et al. Belgian consensus on metabolic problems associated with atypical antipsychotics. Int J Psychiatry Clin Pract 2005; 9(2): 130–7CrossRefGoogle Scholar
  42. 42.
    Linden M, Scheel T, Eich FX. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride. J Psychopharmacol 2006 Nov; 20(6): 815–23PubMedCrossRefGoogle Scholar
  43. 43.
    Linden M, Eich FX, Pyrkosch L. Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride. Int Clin Psychopharmacol 2007 May; 22(3): 175–8PubMedCrossRefGoogle Scholar
  44. 44.
    Shore D, Matthews S, Cott J, et al. Clinical implications of clozapine discontinuation: report of an NIMH workshop. Schizophr Bull 1995; 21(2): 333–8PubMedCrossRefGoogle Scholar
  45. 45.
    Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep 22; 353(12): 1209–23PubMedCrossRefGoogle Scholar
  46. 46.
    Weiden PJ. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J Clin Psychiatry 2007; 68Suppl. 1: 12–9PubMedGoogle Scholar
  47. 47.
    Borison RL. Changing antipsychotic medication: guidelines on the transition to treatment with risperidone. The Consensus Study Group on Risperidone Dosing. Clin Ther 1996 Jul–Aug; 18(4): 592–607; discussion 591PubMedCrossRefGoogle Scholar
  48. 48.
    Naranjo CA, Sproule BA, Knoke DM. Metabolic interactions of central nervous system medications and selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1999 May; 14Suppl. 2: S35–47PubMedGoogle Scholar
  49. 49.
    Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry 1997 Aug; 171: 109–12PubMedCrossRefGoogle Scholar
  50. 50.
    Committee on Safety of Medicines. UK Medicines Control Agency. Drug-induced neutropenia and agranulocytosis. Curr Prob 1993; 10: 10–1Google Scholar
  51. 51.
    Chong SA, Tan CH, Lee HS. Atrial ectopics with clozapine-risperidone combination. J Clin Psychopharmacol 1997 Apr; 17(2): 130–1PubMedCrossRefGoogle Scholar
  52. 52.
    Carriere P, Bonhomme D, Lemperiere T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry. 2000 Aug; 15(5): 321–9PubMedCrossRefGoogle Scholar
  53. 53.
    Chabannes JP, Pelissolo A, Farah S, et al. Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses [in French]. Encephale 1998 Jul–Aug; 24(4): 386–92PubMedGoogle Scholar
  54. 54.
    Speller JC, Barnes TR, Curson DA, et al. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms: amisulpride v. haloperidol. Br J Psychiatry 1997 Dec; 171: 564–8PubMedCrossRefGoogle Scholar
  55. 55.
    Wetzel H, Grander G, Hillert A, et al. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology: a double-blind controlled study comparing a selective D2-like antagonist to a mixed Dl-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology (Berl) 1998 Jun; 137(3): 223–32CrossRefGoogle Scholar
  56. 56.
    Lambert M, Naber D, Eich FX, et al. Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatr Scand 2007 Feb; 115(2): 106–13PubMedCrossRefGoogle Scholar
  57. 57.
    Lerner V, Libov I, Kotier M, et al. Combination of ‘atypical’ antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004 Jan; 28(1): 89–98PubMedCrossRefGoogle Scholar
  58. 58.
    Zink M, Dressing H. Augmenting atypical antipsychotic medications with clozapin [in German]. Nervenarzt 2005 Sep; 76(9): 1092, 4–8, 100-2PubMedCrossRefGoogle Scholar
  59. 59.
    Agelink MW, Kavuk I, Ak I. Clozapine with amisulpride for refractory schizophrenia. Am J Psychiatry 2004 May; 161(5): 924–5PubMedCrossRefGoogle Scholar
  60. 60.
    Buckley P, Miller A, Olsen J, et al. When symptoms persist: clozapine augmentation strategies. Schizophr Bull 2001; 27(4): 615–28PubMedCrossRefGoogle Scholar
  61. 61.
    Zink M, Henn FA, Thome J. Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses. Eur Psychiatry 2004 Feb; 19(1): 56–8PubMedCrossRefGoogle Scholar
  62. 62.
    Kämpf P, Agelink MW, Naber D. Augmentation of clozapine with amisulpride: a promising therapeutic approach to refractory schizophrenic symptoms. Pharmacopsychiatry 2005 Jan; 38(1): 39–40PubMedCrossRefGoogle Scholar
  63. 63.
    Kämpf P, Agelink MW, Mass R, et al. Amisulpride in addition to clozapine: a retrospective study indicates improved efficacy and good tolerability. German J Psychiatry 2003; 6: 64–8Google Scholar
  64. 64.
    Munro J, Matthiasson P, Osborne S, et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand 2004 Oct; 110(4): 292–8PubMedCrossRefGoogle Scholar
  65. 65.
    Ziegenbein M, Wittmann G, Kropp S. Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation. Clin Drug Invest 2006; 26(3): 117–24CrossRefGoogle Scholar
  66. 66.
    Schoemaker H, Claustre Y, Fage D, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997 Jan; 280(1): 83–97PubMedGoogle Scholar
  67. 67.
    Assion HJ, Reinbold H, Lemanski S, et al. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine: a randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 2008 Jan; 41(1): 24–8PubMedCrossRefGoogle Scholar
  68. 68.
    Genç Y, Taner E, Candansayar S. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther 2007 Jan–Feb; 24(1): 1–13PubMedCrossRefGoogle Scholar
  69. 69.
    Ziegenbein M, Sieberer M, Kuenzel HE, et al. Augmentation of clozapine with amisulpride in patients with treatment-resistant schizophrenia: an open clinical study. Germ J Psychiatr 2006; 9: 17–21Google Scholar
  70. 70.
    Zink M, Knopf U, Henn FA, et al. Combination of clozapine and amisulpride in treatment-resistant schizophrenia: case reports and review of the literature. Pharmacopsychiatry 2004 Jan; 37(1): 26–31PubMedCrossRefGoogle Scholar
  71. 71.
    Cook B, Hoogenboom G. Combined use of amisulpride and clozapine for patients with treatment-resistant schizophrenia. Australas Psychiatry 2004 Mar; 12(1): 74–6PubMedCrossRefGoogle Scholar
  72. 72.
    Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol 2006 Mar; 21(2): 99–103PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Luca Pani
    • 1
    • 2
  • José M. Villagrán
    • 3
  • Vassilis P. Kontaxakis
    • 4
  • Köksal Alptekin
    • 5
  1. 1.Institute of Biomedical Technologies, National Research Council (CNR)MilanItaly
  2. 2.PharmaNess ScarlSardegna RicerchePula (Cagliari)Italy
  3. 3.Psychiatric Hospitalization UnitJerez Hospital, Andalusian Health ServiceCádizSpain
  4. 4.University of Athens, Eginition HospitalAthensGreece
  5. 5.Department of Psychiatry, School of MedicineUniversity of Dokuz EylülIzmirTurkey

Personalised recommendations